SMFM statement on NIH treatment guidelines

Article

SMFM supports the new NIH COVID-19 Treatment guidelines.

SMFM supports the new NIH COVID-19 Treatment guidelines.

The following pertains to treatment for pregnant patients:

  • Paxlovid (nirmatrelvir [PF-07321332] tablets and ritonavir tablets): no pregnancy data on nirmetrelvir, limited supply, consider drug-drug interactions
  • Sotrovimab: limited supply that is mostly reserved for highest risk immunocompromised and elderly
  • Remdesivir (3 day outpatient regimen): extensive pregnancy experience but requires multiple infusions

All of the above have similar efficacy at preventing hospitalization and death; despite no pregnancy-specific data

  • Molnupiravir: 30% efficacy; EUA recommends against use in pregnancy but may reasonably consider use in pregnancy if no other therapies available and with documented counseling

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Related Content
© 2025 MJH Life Sciences

All rights reserved.